However, these results imply that the overexpression of EZH2 and under-expression of FOXO1 are the main characteristics of CRC drug resistance and metastasis, with SFMBT1 and HMG20A identified as possible targets for therapeutic agents to increase drug resistance. Here, SFMBT1 is linked to colorectal carcinoma.